Medicover stock drops amid acquisition news

Published 02/04/2025, 09:22
© Reuters.

Investing.com -- Shares of Medicover (STO:MCOV) fell by 2.7% today after the healthcare and diagnostic services provider announced the acquisition of Synlab’s businesses in various European countries. The deal, valued at €71.3 million, is set to expand Medicover’s footprint into three new markets but has raised concerns among investors.

The acquisition, which will be consolidated from the second quarter of 2025, includes operations in Romania, Turkey, Cyprus, Slovenia, Croatia, and North Macedonia.

These businesses generated revenue of €48 million in the fiscal year 2024. Medicover expects the deal to be accretive to earnings per share upon consolidation and projects to achieve more than 50% of the current profitability of the acquired entities within the next 12 months and over 100% in the subsequent 12 months.

The company has outlined plans to generate synergies by centralizing advanced testing volumes and procurement.

The acquisition is fully financed through Medicover’s existing committed loan facilities, which may have contributed to investor concerns about the financial impact and the integration of the new businesses.

Analysts at Jefferies commented on the acquisition, noting potential benefits in the longer term: "Assuming a 5-10% EBITDA margin in FY24 and the margin expansion progresses as detailed, implies the acquisition could grow FY26 group Adj. EBITDA by <3.0%."

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.